To this end, we have determined the ex vivo cellular bioenergetic metabolic profile of CLL patients, both untreated and with a history of prior treatment, evaluating the correlation between cellular bioenergetic signature, clinical/biological characteristics, and response to BTK inhibitor treatment. Here, BTK is linked to B-cell chronic lymphocytic leukemia.